pathogenesi
highli
pathogen
middl
east
respiratori
syndrom
coronaviru
merscov
remain
poorli
understood
previou
studi
establish
mous
model
merscov
infect
caus
sever
acut
respiratori
failur
high
mortal
accompani
elev
secret
cytokin
chemokin
sinc
excess
complement
activ
import
factor
contribut
acut
lung
injuri
viral
infect
studi
investig
role
complement
merscovinduc
lung
damag
studi
show
complement
excess
activ
merscovinfect
mice
observ
increas
concentr
complement
activ
product
sera
lung
tissu
respect
interestingli
block
product
target
receptor
allevi
lung
spleen
tissu
damag
reduc
inflammatori
respons
importantli
antibodi
treatment
led
decreas
viral
replic
lung
tissu
furthermor
compar
sham
treatment
control
apoptosi
splenic
cell
less
pronounc
splenic
white
pulp
treat
mice
greater
number
prolifer
splenic
cell
particularli
red
pulp
observ
data
indic
dysregul
host
immun
respons
contribut
sever
outcom
mer
excess
complement
activ
trigger
merscov
infect
promot
dysregul
blockad
axi
lead
decreas
tissu
damag
induc
merscov
infect
manifest
reduc
apoptosi
cell
regener
spleen
therefor
result
studi
suggest
new
strategi
clinic
intervent
adjunct
treatment
merscov
case
middl
east
respiratori
syndrom
coronaviru
merscov
first
emerg
novemb
saudi
arabia
februari
mer
report
countri
laboratoryconfirm
case
includ
death
mortal
rate
merscov
similar
sever
acut
respiratori
syndrom
coronaviru
sarscov
genu
merscov
caus
outbreak
fatal
rate
merscov
lead
progress
sever
pneumonia
infect
patient
diffus
alveolar
damag
occur
acut
phase
sever
infect
accompani
consider
extrapulmonari
organ
dysfunct
later
phase
sarscov
infect
shown
lack
type
interferon
respons
caus
lymphopenia
decreas
number
cell
acut
phase
howev
mechan
contribut
sever
clinic
symptom
merscov
infect
still
elucid
owe
absenc
autopsi
studi
limit
data
vitro
ex
vivo
studi
indic
merscov
induc
substanti
cytopath
effect
dysregul
host
immun
respons
similar
sarscov
compar
studi
sarscov
infect
immunemedi
pathogenesi
propos
potenti
factor
sever
outcom
merscovinfect
patient
sar
patient
show
hyperimmun
activ
includ
aberr
express
interferon
ifn
stimul
gene
cytokin
respons
like
succumb
sarscov
infect
sever
correl
amount
inflammatori
cytokin
present
serum
clinic
data
pathogenesi
merscov
infect
spars
josset
et
al
report
merscov
significantli
downregul
express
gene
involv
antigen
present
pathway
turn
could
affect
develop
adapt
immun
respons
addit
proinflammatori
cytokin
markedli
induc
cell
merscov
infect
zhou
et
al
also
specul
cytokin
storm
could
correl
sever
ill
sinc
high
level
proinflammatori
cytokin
chemokin
observ
secret
human
macrophag
upon
merscov
infect
previous
observ
aberr
immun
respons
merscovinfect
mice
elev
secret
cytokin
protein
tumor
necrosi
close
associ
viral
mediat
acut
lung
injuri
nevertheless
role
merscovinduc
excess
inflammatori
respons
factor
contribut
sever
diseas
outcom
need
studi
complement
system
play
import
role
host
defens
microbi
infect
maintain
immun
homeostasi
howev
complement
also
contribut
pathogenesi
mani
inflammatori
immunolog
diseas
excess
inappropri
activ
biolog
effector
function
complement
mediat
primarili
split
product
ie
promot
inflamm
via
direct
indirect
mechan
upon
interact
respect
receptor
receptor
receptor
addit
serv
potent
chemoattract
also
activ
leukocyt
stimul
releas
granzym
stimul
phagocytosi
respiratori
burst
mononuclear
cell
furthermor
induc
mononuclear
cell
express
vitro
enhanc
releas
vivo
antibodi
ab
blockad
report
abrog
excess
immun
respons
mous
model
plasmodium
berghei
anka
infect
previou
studi
use
mous
model
nonhuman
primat
model
inhibit
overactiv
complement
system
allevi
virusinduc
acut
lung
injuri
high
pathogen
accompani
increasingli
sever
dysregul
immun
respons
merscovinfect
patient
prompt
us
explor
potenti
role
complement
pathogenesi
merscov
therefor
studi
demonstr
merscov
infect
induc
complement
overactiv
led
sever
lung
damag
blockad
interact
allevi
tissu
injuri
reestablish
normal
local
system
immun
respons
includ
reduc
infiltr
tissu
macrophag
inflammatori
cytokin
express
apoptosi
splenic
cell
increas
cell
regener
therefor
suggest
complement
inhibit
may
promis
intervent
strategi
treat
merscovinfect
patient
procedur
involv
anim
approv
laboratori
anim
center
state
key
laboratori
pathogen
biosecur
beij
institut
microbiolog
epidemiolog
iacuc
permit
number
bime
anim
studi
carri
strict
accord
recommend
guid
care
use
laboratori
anim
experiment
oper
mice
perform
sodium
pentobarbit
anesthesia
mice
euthan
overdos
inhal
carbon
dioxid
sixweekold
femal
mice
maintain
pathogenfre
facil
hous
cage
contain
steril
feed
drink
water
merscov
strain
propag
titrat
vero
cell
follow
intraperiton
anesthet
sodium
pentobarbit
mgkg
bodi
weight
mice
treat
intraven
iv
monoclon
ab
mab
mous
hycult
biotech
netherland
phosphatebuff
salin
pb
sham
treatment
control
mice
intranas
inocul
merscov
tissu
cultur
infecti
dose
tcid
dulbecco
modifi
eagl
medium
infecti
experi
relat
merscov
perform
approv
biosafeti
level
facil
lung
spleen
collect
sampl
accord
standard
procedur
section
thick
stain
hematoxylin
eosin
examin
light
microscopi
lung
tissu
lesion
assess
accord
extent
denatur
epitheli
tissu
degener
necrosi
alveoli
pneumocyt
infiltr
inflammatori
cell
expans
parenchym
wall
hemorrhag
interstiti
edema
section
paraffinembed
spleen
lung
tissu
thick
prepar
detect
antigen
express
immunohistochemistri
ihc
stain
briefli
retriev
section
incub
overnight
follow
antibodi
mous
mab
hycult
biotech
netherland
rabbit
calbiochem
santa
cruz
biotechnolog
paso
robl
ca
usa
polyclon
antibodi
rabbit
abcam
cambridg
usa
santa
cruz
biotechnolog
polyclon
antibodi
rabbit
cleav
ab
cell
signal
mous
antipcna
mab
santa
cruz
biotechnolog
rabbit
novel
coronaviru
nucleoproteinnp
polyclon
ab
sino
biolog
inc
beij
china
biotinyl
immunoglobulin
g
ad
follow
avidinbiotinperoxidas
conjug
beij
zhongshan
biotechnolog
co
ltd
immunoreact
detect
use
diamino
benzidin
dab
counterstain
hematoxylin
detect
express
lung
tissu
lung
sampl
harvest
total
rna
extract
purifi
use
rneasi
extract
kit
qiagen
germani
sampl
total
rna
use
templat
firststrand
cdna
synthesi
result
cdna
subject
quantit
pcr
use
power
sybr
green
pcr
master
mix
life
technolog
carlsbad
ca
usa
determin
rel
abund
tissu
forward
revers
primer
use
previous
describ
rel
amount
determin
normal
mrna
express
endogen
control
gene
gapdh
cytokin
chemokin
mous
sera
measur
use
milliplex
mous
cytokinechemokin
magnet
panel
kit
merck
millipor
usa
panel
inflammatori
cytokin
chemokin
keratinocyt
chemoattract
kc
monocyt
chemotact
detect
accord
manufactur
protocol
section
paraffinembed
spleen
thick
prepar
assess
splenic
cell
apoptosi
use
tdt
situ
apoptosi
detect
kitdab
tunel
termin
deoxynucleotidyl
transferas
dutp
nickend
label
base
apoptosi
detect
assay
accord
manufactur
protocol
roch
germani
briefli
dewax
treatment
proteinas
k
section
label
label
solut
signal
convers
use
coverterpod
signal
detect
analyz
light
microscopi
number
apoptot
cell
random
highpow
field
hpf
magnif
calcul
result
express
tunelposit
cellshpf
lung
tissu
infect
mice
harvest
asept
indic
time
point
homogen
minim
essenti
medium
mem
plu
antibiot
produc
wv
suspens
tissu
homogen
centrifug
titer
monolay
vero
cell
cytopath
effect
cpe
observ
daili
via
phasecontrast
microscopi
day
viral
titer
determin
tcid
use
cpebas
assay
calcul
use
reed
muench
method
viral
titer
express
log
tcid
g
lung
tissu
statist
analys
perform
use
graphpad
prism
version
student
test
use
compar
treatment
sham
group
assess
semiquantit
histopatholog
damag
viral
rna
copi
titer
lung
inflammatori
cytokinechemokin
level
semiquantit
splenocyt
apoptosi
regener
compar
express
level
sera
lung
tissu
respect
oneway
analysi
varianc
dunnett
posttest
use
signific
surviv
curv
analyz
kaplanmei
surviv
analysi
logrank
test
p
valu
lower
consid
signific
determin
whether
local
complement
activ
relat
lung
damag
merscov
infect
examin
complement
activ
lung
tissu
result
show
deposit
increas
viral
infect
fig
express
lung
also
increas
especi
bronchu
epitheli
cell
pneumocyt
inflammatori
cell
detect
immunohistochemistri
stain
fig
f
rel
express
transcript
level
also
confirm
increas
complement
express
lung
tissu
day
postinfect
fig
furthermor
presenc
sera
indic
complement
activ
detect
enzymelink
immunosorb
assay
result
show
mer
cov
infect
concentr
increas
day
decreas
day
postinfect
fig
specul
merscov
infect
could
promptli
induc
activ
local
system
complement
activ
subsequ
virusinfect
host
may
initi
selfprotect
mechan
suppress
overactiv
complement
respons
result
observ
decreas
product
howev
continu
viral
replic
may
eventu
overcom
host
respons
lead
stronger
complement
activ
rebound
product
find
suggest
close
relationship
system
inflammatori
respons
local
tissu
damag
although
complement
promptli
activ
viral
infect
confirm
efficaci
ab
treatment
compar
sham
treatment
control
measur
local
system
inflamm
mous
lung
day
postinfect
treatment
macrophag
infiltr
decreas
lung
tissu
mice
fig
b
express
receptor
primarili
express
inflammatori
cell
also
decreas
detect
immunohistochemistri
fig
furthermor
concentr
proinflammatori
cytokin
decreas
level
chemokin
significantli
decreas
ab
treatment
group
signific
differ
concentr
detect
treatment
control
group
fig
eb
overal
result
suggest
ab
treatment
could
decreas
local
system
inflamm
especi
thelper
type
immun
respons
induc
merscov
infect
may
also
contribut
tissu
damag
merscov
infect
determin
complement
activ
influenc
viral
replic
viral
titer
lung
tissu
well
antigen
express
assess
compar
pb
treatment
group
result
show
lung
tissu
exhibit
less
viral
antigen
express
fig
b
lower
viral
titer
viral
replic
fig
ab
treatment
group
result
indic
inhibit
complement
activ
could
limit
merscov
replic
lung
histopatholog
studi
day
postinfect
show
merscov
infect
induc
mild
sever
interstiti
pneumonia
diffus
thicken
alveolar
septa
accompani
infiltr
lymphocyt
macrophag
neutrophil
denatur
collaps
pneumocyt
multifoc
hemorrhag
interstiti
space
lung
fig
therefor
elucid
role
excess
complement
activ
infecti
merscovinduc
tissu
damag
mab
mous
receptor
use
block
interact
receptor
treatment
damag
lessen
mild
focal
thicken
alveolar
septa
observ
especi
around
vessel
edema
hemorrhag
lung
observ
fig
semiquantit
analysi
also
confirm
rel
less
sever
damag
lung
tissu
fig
addit
blockad
decreas
weight
loss
observ
one
mous
left
aliv
compar
observ
sham
treatment
group
fig
although
singl
mous
surviv
treatment
signific
result
indic
blockad
axi
could
allevi
lung
damag
mice
although
antivir
agent
inhibit
merscov
infect
may
requir
combin
ab
increas
surviv
rate
merscovinfect
mice
clinic
merscovinfect
patient
shown
atyp
pneumonia
dysregul
inflammatori
respons
spleen
import
peripher
lymphoid
organ
abl
produc
immun
respons
immedi
viral
infect
test
hypothesi
blockad
interact
may
reduc
spleen
damag
spleen
tissu
examin
merscovinfect
mice
without
treatment
ab
result
show
signific
number
splenic
cell
present
necrosi
apoptosi
especi
white
pulp
yellow
arrow
numer
inflammatori
cell
infiltr
red
pulp
fig
c
e
interestingli
mice
provid
ab
treatment
exhibit
less
spleen
damag
less
splenic
cell
necrosi
apoptosi
increas
number
macrophag
detect
red
pulp
blue
arrow
fig
f
howev
merscov
replic
viral
antigen
express
observ
spleen
mice
treat
untreat
group
data
shown
collect
find
suggest
damag
spleen
tissu
caus
merscov
replic
splenocyt
may
result
dysregul
immun
inflammatori
respons
caus
merscov
infect
lung
suscept
organ
importantli
ab
treatment
could
significantli
attenu
spleen
damag
suggest
dysregul
immun
inflammatori
respons
like
close
associ
complement
system
host
lymphopenia
primari
clinic
aspect
sever
ill
patient
merscov
infect
mice
observ
increas
apoptosi
splenic
cell
confirm
detect
apoptosisposit
cell
immunohistochemistri
cleav
tunel
method
fig
c
comparison
less
apoptosi
splenic
cell
observ
spleen
ab
treatment
group
fig
g
interestingli
increas
splenic
cell
regener
clearli
evid
red
pulp
mice
ab
treatment
confirm
detect
pcna
express
spleen
ihc
stain
fig
f
h
next
evalu
effect
ab
treatment
viral
titer
inflamm
brain
includ
olfactori
bulb
cerebr
cortex
hippocampu
day
postinfect
result
show
less
viral
antigen
less
activ
microglia
brain
abtreat
mice
compar
untreat
mice
data
shown
result
suggest
treatment
could
also
suppress
inflammatori
respons
allevi
damag
brain
tissu
caus
merscov
infect
collect
result
suggest
sever
outcom
merscov
infect
relat
host
lymphopenia
may
close
relat
overactiv
complement
system
howev
blockad
axi
could
decreas
damag
lung
spleen
brain
tissu
caus
merscov
infect
accord
compar
studi
sarscov
patient
limit
clinic
data
merscov
patient
immunemedi
pathogenesi
propos
potenti
factor
sever
outcom
merscovinfect
patient
studi
human
transgen
mous
model
previous
develop
use
investig
whether
merscov
infect
caus
aberr
system
inflammatori
respons
one
may
question
whether
human
protein
express
tg
mous
may
caus
dysregul
immun
inflammatori
respons
sinc
function
signal
protein
surfac
cell
enzym
cleav
chemokin
cytokin
lung
brain
costimulatori
molecul
induc
cell
prolifer
howev
previou
studi
observ
wildtyp
mice
similar
present
immun
respons
without
merscov
infect
data
shown
addit
tseng
group
observ
dysregul
immun
inflammatori
respons
mice
viral
challeng
result
suggest
human
protein
express
tg
mous
may
significantli
influenc
immun
inflammatori
respons
mice
possibl
differ
speci
result
studi
confirm
aberr
system
inflammatori
respons
especi
mediat
dysregul
complement
system
induc
merscov
infect
may
contribut
sever
outcom
infect
furthermor
block
interact
complement
activ
block
axi
could
promis
strategi
adjunct
treatment
merscov
infect
complement
function
immun
surveil
system
rapidli
respond
viral
infect
play
pivot
role
inflammatori
respons
compar
patient
dengu
fever
df
sever
ill
patient
dengu
hemorrhag
fever
dhf
dengu
shock
syndrom
shown
higher
level
cleavag
product
specif
fd
cleav
fb
yield
activ
convertas
lower
level
fh
inactiv
convertas
addit
high
level
observ
present
plasma
leakag
occur
dhf
patient
moreov
express
complement
inhibitor
gene
upregul
strongli
peripher
blood
mononuclear
cell
df
patient
dhf
patient
studi
implic
role
complement
system
pathogenesi
sever
form
dengu
virusassoci
diseas
ross
river
viru
rrv
induc
complementdefici
mous
model
less
sever
tissu
damag
diseas
symptom
follow
rrv
infect
also
indic
import
role
complement
rrvinduc
pathogenesi
previou
studi
highli
pathogen
influenza
viru
infect
dysregul
complement
activ
observ
accompani
sever
lung
damag
suggest
aberr
complement
regul
may
import
caus
factor
viru
infect
import
proinflammatori
polypeptid
mediat
strong
proinflammatori
immun
modulatori
signal
mani
diseas
exampl
induc
express
mononuclear
cell
vitro
enhanc
releas
vivo
studi
aberr
complement
activ
confirm
lung
tissu
mice
merscov
infect
prompt
us
investig
contribut
complement
outcom
merscov
infect
expect
block
axi
lung
injuri
allevi
merscov
infect
less
tissu
damag
accompani
decreas
infiltr
lung
tissu
macrophag
decreas
fig
allevi
lung
damag
mice
blockad
af
hematoxylin
eosin
h
e
stain
lung
tissu
section
obtain
day
ab
treatment
lung
tissu
sham
treatment
group
present
mild
sever
interstiti
pneumonia
wherea
treatment
group
less
sever
mild
focal
thicken
alveolar
septa
g
semiquantit
histopatholog
analysi
h
estain
lung
section
day
challeng
p
student
ttest
welch
correct
hi
bodi
weight
surviv
rate
challeng
addit
six
mice
group
weigh
monitor
experi
repeat
data
one
repres
experi
two
experi
present
system
inflammatori
respons
especi
immun
respons
detect
level
sera
previou
studi
base
infect
human
macrophag
dendrit
cell
indic
merscov
significantli
induc
express
inflammatori
chemotact
cytokin
well
chemokin
macrophag
dendrit
cell
host
immun
respons
trigger
merscov
infect
doubleedg
sword
may
help
suppress
viral
infect
caus
sever
lung
damag
shown
studi
importantli
determin
blockad
interact
ab
could
significantli
reduc
alveolar
macrophag
infiltr
receptor
express
lung
tissu
result
allevi
tissu
damag
induc
excess
immun
respons
spleen
import
secondari
lymphoid
organ
wellorgan
structur
allow
captur
process
present
antigen
ultim
lead
success
elimin
pathogen
induct
adapt
immun
thu
spleen
pivot
maintain
blood
homeostasi
produc
immun
respons
viral
infect
spleen
divid
white
red
pulp
separ
margin
zone
vast
splenic
macrophag
popul
margin
metallophil
macrophag
margin
zone
macrophag
red
pulp
macrophag
consid
play
import
role
control
infect
well
induct
innat
adapt
immun
exampl
red
pulp
macrophag
prevent
autoimmun
produc
antiinflammatori
cytokin
induc
tregulatori
cell
cytokin
may
import
curb
excess
immun
respons
could
deleteri
host
pathogen
clearanc
studi
increas
number
macrophag
splenic
red
pulp
decreas
concentr
sera
observ
treatment
group
compar
fig
blockad
mice
increas
splenic
cell
regener
decreas
splenic
cell
apoptosi
b
apoptosi
splenic
cell
assess
immunohistochem
stain
cleav
spleen
tissu
day
challeng
c
apoptosi
splenic
cell
detect
use
dab
tunelbas
apoptosi
detect
assay
spleen
tissu
day
challeng
e
f
repres
imag
regener
splenic
cell
detect
ihc
stain
pcna
day
challeng
g
apoptosi
index
splenocyt
assess
accord
tunelbas
apoptosi
detect
spleen
section
day
challeng
h
semiquantit
analysi
pcnaposit
cell
spleen
section
day
challeng
n
per
group
sham
treatment
group
indic
ab
treatment
may
decreas
excess
complement
immun
respons
induc
merscov
infect
clinic
lymphopenia
occur
mani
infecti
diseas
influenza
hiv
hypotosi
sepsi
lymphopenia
also
commonli
observ
mer
patient
complement
inhibit
decayacceler
factor
shown
regul
cell
immun
viru
infect
ward
colleagu
ward
demonstr
play
crucial
role
develop
septic
lymphopenia
target
prevent
lymphopenia
consid
restor
normal
immun
respons
lieu
afterthefact
strategi
chu
et
al
demonstr
merscov
infect
induc
apoptosi
human
primari
lymphocyt
involv
caspasedepend
apoptosi
pathway
studi
confirm
merscov
contribut
apoptosi
splenic
cell
vivo
accompani
sever
spleen
damag
dysregul
system
immun
respons
indic
cell
play
role
control
pathogenesi
merscov
infect
possibl
regul
host
immun
respons
complement
improv
statu
spleen
tissu
decreas
splenic
apoptosi
increas
regener
splenic
cell
indic
induct
product
merscov
infect
may
contribut
dysregul
immun
respons
blockad
axi
may
improv
outcom
restor
normal
immun
respons
summari
studi
demonstr
merscov
infect
result
dysregul
host
immun
respons
contribut
sever
outcom
observ
infect
howev
blockad
interact
could
allevi
tissu
damag
induc
merscov
infect
regul
host
immun
respons
especi
apoptosi
regener
cell
spleen
studi
suggest
new
effect
clinic
intervent
adjunct
treatment
merscov
infect
